Business Context and Reporting Period
This Form 6-K filing by GSK plc reports the results of the 26th Annual General Meeting (AGM) held on May 6, 2026. The meeting was conducted as a hybrid event in London, allowing for both in-person and virtual shareholder participation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
All 25 resolutions presented at the AGM were passed. Key voting statistics include:
- Shareholder Participation: 76.38% to 76.48% of issued share capital was voted across resolutions, representing an increase from the 74.21% participation rate in the 2025 AGM.
- Board Elections: All director re-elections and the election of new director Luke Miels passed with support ranging from 98.18% to 99.84%.
- Remuneration: The Annual Report on Remuneration passed with 96.74% support, while the Remuneration Policy passed with 98.96% support.
- Capital Authority: Resolutions regarding share allotment, disapplication of pre-emption rights, and share buyback authority were approved with over 96% support.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves strictly as a record of the AGM proceedings and voting tallies.
Investor Verification Checklist
- Verify the full text of the 2025 Annual Report and Remuneration Policy referenced in the voting resolutions on the GSK website.
- Confirm the specific terms of the share buyback authority and pre-emption rights disapplication approved in Resolutions 19-22.
- Review the Notice of AGM published on March 25, 2026, for detailed descriptions of the resolutions.
- Check the FCA National Storage Mechanism for copies of special resolutions as required by Listing Rule 6.4.2.